Genmab — Maj 2017
-
Altså: 17. juni er deadline for svar på dara/pom/dex. Er det rigtigt forstået, Sukkeralf?
-
Spændende Sukkeralf.
-
-
Since CD38 is one of the most strongly induced RARα target genes in response to SY-1425, AML blasts can be sensitized to DARA in a biomarker dependent manner. The preclinical synergistic effects and anticipated non-overlapping clinical toxicity profiles of the respective agents provide a strong rationale for clinical evaluation
-
-
On average, 78% of panobinostat-treated primary myeloma cells were eliminated by daratumumab within the 4-hour ADCC assay, whereas only 51% myeloma cells were eliminated without panobinostat treatment (p<0.01). The synergistic anti-myeloma efficacy of panobinostat and daratumumab was confirmed with a panel of myeloma cell lines
-
Our data demonstrate that the HDACi panobinostat induces upregulation of CD38 on myeloma and a subsequent dramatic increase of daratumumab-mediated ADCC. These data suggest that panobinostat could be used synergistically with daratumumab in a clinical setting to increase response rates and extend duration of responses to daratumumab
-
-
Tusinde tak for info Gentogen.
-
Det ser ikke ud til at smoldering-data er med på EHA? Til gengæld er der "opmuntrende" prækliniske data for dara mono i MCL og FL ! http://learningcenter.ehaweb.org/eha/2017/22nd/181145/alba.matas-cspedes.daratumumab.a.novel.human.cd38.monoclonal.antibodyfor.the.html?f=m3e1181
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind